Pennsylvania Superior Court Affirms $725M Exxon Benzene Award in Full

A three-judge panel of the Pennsylvania Superior Court on October 15 affirmed the judgment against Exxon Mobil Corp. in favor of Paul Gill, a former Mobil station mechanic who developed acute myeloid leukemia, leaving in place a $725 million compensatory award to Gill, $500,000 to his wife Diane and the delay damages that bring the judgment to $815,833,561.65.

Exxon had appealed, in Gill v. Exxon Mobil Corp., No. 2811 EDA 2024, from the judgment entered on September 23, 2024 in the Philadelphia Court of Common Pleas, after the trial court denied its motions for judgment notwithstanding the verdict, a new trial or a remittitur and molded the May 9, 2024 jury verdict to add delay damages. Judge Deborah Kunselman wrote the non-precedential memorandum, Judge Carolyn Nichols joined, and Judge Deborah Sullivan filed a statement concurring in part and dissenting in part.

Pennsylvania produced 12 nuclear verdicts worth $3.4 billion in 2024, the Gill award among them, in Marathon Strategies figures Claims Journal reported in May 2025. Marshall Dennehey's August 2026 count puts the state at 42 personal-injury verdicts above $10 million between June 2021 and May 2026, 29 of them in Philadelphia, of which five were reversed or reduced.

Key Takeaways

Gill's award was entirely non-economic: $435 million for pain and suffering, $253.75 million for loss of enjoyment of life and $18.125 million each for embarrassment and disfigurement.
The $725 million is entirely compensatory: the trial court granted Exxon a nonsuit on punitive damages before the case reached the jury.
Exxon asked the trial court to cut the award to $250,000; the Superior Court said it could not reweigh damages de novo.
Judge Sullivan dissented in part, writing that Exxon had a colorable claim that the refusal of remittitur was an abuse of discretion, and would have reviewed the damages on the merits.

What the panel decided

Exxon's lead argument was that the Gills never proved Mobil gasoline contained at least 2% benzene, so the causation opinion of Robert Laumbach, a Rutgers occupational medicine professor, rested on a fact not in evidence. In the trial court, the panel found, Exxon had argued a different point, that no expert said gasoline itself causes AML, and it dismissed the new theory as waived under Pa.R.A.P. 302(a). "Exxon may not make a new argument regarding causation for the first time on appeal," Kunselman wrote.

On the experts, the court applied Pennsylvania's Frye standard and found no abuse of discretion in letting Laumbach and Rory Shallis, a Yale hematologist-oncologist, testify, despite an Atlantic Legal Foundation amicus brief arguing that the trial court's 362-page post-trial opinion quoted only the plaintiffs' experts.

On remittitur, the standard of review decided the issue. Kunselman wrote that the court "may not ask itself whether the jury's award of $725,000,000 in compensation to Mr. Gill was correct or excessive" and could decide only whether the trial court abused its discretion in finding the verdict did not shock its conscience. Exxon's brief, the majority noted, never used the phrase "abuse of discretion" in its damages argument.

Sullivan disagreed on that point. She wrote that Exxon had "stated a colorable argument" that the denial of post-trial relief on damages was an abuse of discretion, and that the trial court's opinion never addressed Exxon's claim that the $18.125 million disfigurement award lacked evidentiary support. She would have conducted a merits review of the damages ruling but joined the rest of the decision.

Exxon's argument that the award was punitive damages "masquerading as a compensatory award" in violation of the Fourteenth Amendment also failed. Punitive damages never reached the jury, because the trial court had granted Exxon a nonsuit on them, and Exxon "cites no case where any court has applied the Due Process Clause of the Fourteenth Amendment to declare a compensatory-damages award unconstitutional," the opinion said. Every dollar of the $725.5 million is compensatory; a 2024 Legal Dive report describing the award as including punitive damages does not match the record.

Exxon's final issue, a request for a new trial based on message-board posts it attributed to a juror, was dismissed as waived because the trial court had ruled the supplemental motion untimely. Those posts, attached to Exxon's motion, claimed the plaintiff had offered to settle for $1.2 million the morning before deliberations.

Component	Amount
Pain and suffering (past, present, future)	$435,000,000
Loss of enjoyment of life	$253,750,000
Embarrassment and humiliation	$18,125,000
Disfigurement	$18,125,000
Diane Gill, loss of consortium	$500,000
Jury verdict, May 9, 2024	$725,500,000
Delay damages added September 12, 2024	$90,333,561.65
Molded judgment	$815,833,561.65

Sources: Gill v. Exxon Mobil Corp., No. 2811 EDA 2024 (Pa. Super. Oct. 15, 2026), Sullivan, J., footnote 1, and majority memorandum. Delay damages are the molded judgment less the verdict.

Exxon's remittitur bid

Exxon's post-trial motion asked the trial court to cut the award to $250,000 after a 10-2 jury vote for the plaintiffs, The Texas Lawbook reported on May 29, 2024. On September 12, 2024 the trial court denied the motion as meritless and granted the Gills' motion to mold the verdict, and both rulings now stand.

Published data on post-verdict reductions is thin. A 2007 study by David Hyman, Bernard Black and co-authors in the Journal of Empirical Legal Studies matched Texas medical malpractice verdicts to payouts from 1988 to 2003 and found that for adjusted verdicts above $2.5 million, 98% of plaintiffs took a haircut, with a mean reduction of 56%. Insurance policy limits were the main driver, with damages caps second, and remittitur "accounts for only a small share of haircuts," the authors found.

Marathon Strategies' nuclear verdict totals "don't reflect reductions, remittiturs, or reversals," Claims Journal noted in its May 2025 report on the firm's 2024 data. Marshall Dennehey shareholders John Hare and Holli Archer, writing in August 2026, named two of Pennsylvania's five reductions: a $19 million medical malpractice verdict overturned in Newlin v. Vita Healthcare Group and a $14 million verdict remitted to $8 million in Dawson v. Bayada Home Health Care.

Exxon said in May 2024 that the verdict was "irrational" and that it would "exhaust all available appeals," The Philadelphia Inquirer reported. Andrew DuPont, a partner at Locks Law Firm, which represented the Gills, said in a firm statement on October 15 that the decision "confirms what the jury found."

Delay damages and the interest clock

Pennsylvania's Rule 238 adds delay damages to compensatory awards for bodily injury at the plaintiff's request, calculated at the Wall Street Journal prime rate for each calendar year plus 1%, not compounded, from one year after service of the complaint to the date of the verdict. Time after a defendant's written settlement offer is excluded if the recovery does not exceed 125% of the offer. Because the Gills filed suit in May 2020, the clock ran roughly three years to the May 2024 verdict and produced $90.3 million on $725.5 million.

Rule 238 stops at the verdict. From that date the judgment bears interest at the lawful rate under 42 Pa.C.S. Section 8101, so the balance Exxon faces has been accruing since May 9, 2024 through the Superior Court's February 2026 argument and the October 15 decision. On an open Pennsylvania toxic-tort claim the two run in sequence: delay damages from the second year of suit, judgment interest from the verdict.

The Philadelphia docket

Philadelphia's Court of Common Pleas sits fifth in the American Tort Reform Association's 2025-2026 Judicial Hellholes list released December 9, 2025, cited for mass-torts litigation, according to a Duane Morris summary of the report. Atlantic Legal's amicus brief called the court "notoriously plaintiff-friendly." Marathon's 2024 count for the venue included the $2.2 billion, $175 million and $78 million Roundup verdicts against Bayer alongside the Gill award.

Locks called the award the largest ever in a benzene case, according to Insurance Journal's September 2024 report, and the Inquirer described it as "sizable for a suit filed by a single plaintiff not part of a class-action suit."

Two days before the Superior Court ruled, a Philadelphia jury returned a defense verdict for Exxon. On October 13, jurors in a suit by Leon and Ruth Mazza found Exxon's gasoline lacked an adequate benzene warning but was not defectively designed, that the company did not intentionally conceal benzene's dangers, and rejected the claim that gasoline and other automotive products caused Leon Mazza's leukemia, the Pennsylvania Record reported on October 19. Locks was plaintiffs' counsel in that case too.